New Delhi: Drug firm Ranbaxy Laboratories has said its US arm has received a notice from Watson Laboratories Inc, challenging the patent of acne treatment drug Absorica.
The drug is licensed to Ranbaxy Laboratories from Cipher Pharmaceuticals Inc of Mississauga, Ontario. It is currently protected by two issued patents listed in the FDA's approved drug products list, which expire in September 2021, the company said in a statement.
